covernewsall.com
Century Aluminum: A Strong Buy with Significant Growth Potential
FinanceSuze OrmanJun 03, 2026, 2:27 PM

Century Aluminum: A Strong Buy with Significant Growth Potential

Century Aluminum (CENX) is positioned for substantial growth, with a projected 50% upside over the next 12-16 months. This positive outlook is fueled by industry-wide aluminum deficits and robust pricing. The company's impressive Q1 adjusted EBITDA of $231 million, with Q2 guidance set at $315–335 million, highlights its strong financial performance. Furthermore, a 40% stake in a new US smelter joint venture and anticipated share buybacks after 2026 are expected to drive long-term value.

Ulta Beauty: A Steady Performer in the Dynamic Beauty Market
FinanceMorgan HouselJun 03, 2026, 2:27 PM

Ulta Beauty: A Steady Performer in the Dynamic Beauty Market

Ulta Beauty presents a compelling investment opportunity, boasting a P/E ratio of 17.5x, strong Q1 earnings, and a consistent growth trajectory. The company's expansion strategies, diverse revenue streams, and robust customer loyalty program underpin its long-term potential. While acknowledging some concerns like inorganic growth and reliance on buybacks, these are balanced by its attractive valuation and market resilience. I recommend a 'buy' rating for ULTA, anticipating continued revenue growth, stable margins, and a potential re-rating of its market value.

easyJet Acquisition Bid: A Deeper Look into Valuation and Regulatory Challenges
FinanceMorgan HouselJun 03, 2026, 2:27 PM

easyJet Acquisition Bid: A Deeper Look into Valuation and Regulatory Challenges

easyJet's stock experienced a significant rise following Castlelake's acquisition interest. This analysis delves into the proposed takeover's potential regulatory hurdles and evaluates easyJet's intrinsic value. Despite recent challenges from fuel price increases and global events, easyJet maintains a robust financial position and substantial asset backing, suggesting that the current bid may undervalue the airline's real worth, particularly its aircraft fleet.

Featured Articles

01 / LATEST EDITIONS
Allspring Ultra Short-Term Municipal Income Fund Q1 2026 Performance Review
FinanceNouriel RoubiniJun 03, 2026, 2:27 PM

Allspring Ultra Short-Term Municipal Income Fund Q1 2026 Performance Review

The Allspring Ultra Short-Term Municipal Income Fund (SMAIX) underperformed its benchmark, the Bloomberg 1-Year Municipal Bond Index, in Q1 2026. While yield curve positioning and individual security selection negatively impacted returns, the fund benefited from its sector and credit-quality allocations, particularly an overweight to A-rated bonds. The fund is positioned for neutral duration, anticipating strong inflows and record issuance, with a focus on income amid expected rate volatility.

HDFC Bank Faces Decline Amidst Merger Integration and Leadership Change in Q1
FinanceMariana MazzucatoJun 03, 2026, 2:26 PM

HDFC Bank Faces Decline Amidst Merger Integration and Leadership Change in Q1

HDFC Bank Limited (HDB) experienced a downturn in the first quarter of 2026, with its stock price closing at $23.54 per share on June 2, 2026. The bank's shares saw an 8.15% decline over the month and a substantial 37.29% drop over the past 52 weeks, resulting in a market capitalization of $120.82 billion. This underperformance is attributed to challenges in reducing post-merger loan-to-deposit ratios and the unexpected resignation of Chairman Atanu Chakraborty. Despite these hurdles, Brown Advisory Global Leaders Strategy anticipates improvement in LDRs due to strong deposit growth and successful cross-selling initiatives post-merger.

Celcuity's Gedatolisib: A Promising Breast Cancer Treatment Amidst Market Volatility
FinanceNouriel RoubiniJun 03, 2026, 2:26 PM

Celcuity's Gedatolisib: A Promising Breast Cancer Treatment Amidst Market Volatility

Celcuity's stock recently experienced a significant dip despite positive Phase 3 VIKTORIA-1 trial results for gedatolisib, a drug showing superior efficacy in advanced breast cancer treatment. This article delves into the potential of gedatolisib, its market prospects in a multi-billion dollar sector, and the reasons behind the stock's unexpected decline, framing it as a potential buying opportunity.

Trending Reads

02 / CURATED READS
01
Finance
02
Strive MasiyiwaJun 03, 2026, 2:25 PM

Bonds Reemerge as a Key Investment for Retirees

Finance
03
Mariana MazzucatoJun 03, 2026, 2:25 PM

SGA Global Growth Fund Q1 2026 Commentary

Finance

Site Recommendations

03 / IN FOCUS REPORT